Across TCGA pan-cancer cohorts, MIR329-2 Mutation is linked to patient survival in 3 of 34 cancer types, making it the most broadly survival-associated MIR329-2 data layer compared with 3 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MIR329-2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR329-2 expression acts as an unfavorable survival marker.

COAD, LUSC, and SKCM are the cancer types where MIR329-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.111	0.871	<.001	24	view →
LUSC	OS	Median	All	0.005	0.776	<.001	12	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MIR329-2 tumor-vs-normal RNA expression · all MIR329-2 data types